Hypercalcaemia with topical calcipotriol.
作者信息
Bourke J F, Berth-Jones J, Hutchinson P E
出版信息
BMJ. 1993 May 15;306(6888):1344-5. doi: 10.1136/bmj.306.6888.1344-b.
Abstract
摘要
相似文献
1
Hypercalcaemia with topical calcipotriol.伴有局部使用卡泊三醇的高钙血症。
BMJ. 1993 May 15;306(6888):1344-5. doi: 10.1136/bmj.306.6888.1344-b.
2
Hypercalcaemia and hypercalciuria after topical treatment of psoriasis with excessive amounts of calcipotriol.
Acta Derm Venereol. 1999 Jan;79(1):86. doi: 10.1080/000155599750011822.
3
Severe hypercalcemia and hypernatremia associated with calcipotriol for treatment of psoriasis.与用于治疗银屑病的骨化三醇相关的严重高钙血症和高钠血症。
J Bone Miner Metab. 2004;22(2):159-62. doi: 10.1007/s00774-003-0465-z.
4
Hypercalcaemia associated with calcipotriol (Dovonex) treatment.与卡泊三醇（达力士）治疗相关的高钙血症。
BMJ. 1993 Apr 3;306(6882):896. doi: 10.1136/bmj.306.6882.896-a.
5
Hypercalcaemia-induced kidney injury caused by the vitamin D analogue calcitriol for psoriasis: a note of caution when prescribing topical treatment.
Clin Exp Dermatol. 2016 Dec;41(8):899-901. doi: 10.1111/ced.12927. Epub 2016 Oct 20.
6
Generalized pustular psoriasis precipitated by topical calcipotriol cream.
Int J Dermatol. 1994 Jul;33(7):515-6. doi: 10.1111/j.1365-4362.1994.tb02871.x.
7
Hypercalcemia caused by vitamin D3 analogs in psoriasis treatment.
Int J Dermatol. 2007 Dec;46(12):1315-7. doi: 10.1111/j.1365-4632.2007.03347.x.
8
Topical calcipotriol and hypercalcaemia.外用卡泊三醇与高钙血症
Lancet. 1991 May 25;337(8752):1287-8.
9
Hypercalcaemia during treatment of psoriasis with calcipotriol.使用卡泊三醇治疗银屑病期间出现高钙血症。
Br J Dermatol. 1994 Jun;130(6):795-6. doi: 10.1111/j.1365-2133.1994.tb03423.x.
10
Topical treatment with 22-oxacalcitriol (OCT), a new vitamin D analogue, caused severe hypercalcemia with exacerbation of chronic renal failure in a psoriatic patient with diabetic nephropathy; a case report and analysis of the potential for hypercalcemia.用一种新型维生素D类似物22-氧杂骨化三醇（OCT）进行局部治疗，导致一名患有糖尿病肾病的银屑病患者出现严重高钙血症，并加重了慢性肾功能衰竭；病例报告及高钙血症可能性分析
Intern Med. 2003 Dec;42(12):1202-5. doi: 10.2169/internalmedicine.42.1202.
引用本文的文献
1
Safety and efficacy of fixed-dose combination calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) cutaneous foam in adolescent patients (aged 12 to <17 years) with plaque psoriasis: results of a phase II, open-label trial.卡泊三醇（50μg/g）和倍他米松二丙酸酯（0.5mg/g）固定剂量复方皮肤泡沫剂治疗斑块状银屑病青少年患者（年龄12至<17岁）的安全性和有效性：一项II期开放标签试验的结果
J Eur Acad Dermatol Venereol. 2020 Sep;34(9):2026-2034. doi: 10.1111/jdv.16233. Epub 2020 Feb 19.
2
Safety and efficacy of topical, fixed-dose combination calcipotriene (0.005%) and betamethasone (0.064% as dipropionate) gel in adolescent patients with scalp and body psoriasis: a phase II trial.外用固定剂量复方卡泊三醇（0.005%）和倍他米松（二丙酸酯形式为0.064%）凝胶治疗青少年头皮和体部银屑病的安全性和有效性：一项II期试验
J Eur Acad Dermatol Venereol. 2020 May;34(5):1098-1104. doi: 10.1111/jdv.16077. Epub 2020 Jan 2.
本文引用的文献
1
Hypercalcaemia associated with calcipotriol (Dovonex) treatment.与卡泊三醇（达力士）治疗相关的高钙血症。
BMJ. 1993 Apr 3;306(6882):896. doi: 10.1136/bmj.306.6882.896-a.
2
Comparative study of calcipotriol (MC 903) ointment and betamethasone 17-valerate ointment in patients with psoriasis vulgaris.卡泊三醇（MC 903）软膏与倍他米松17-戊酸酯软膏治疗寻常型银屑病的对比研究。
J Am Acad Dermatol. 1992 May;26(5 Pt 1):736-43. doi: 10.1016/0190-9622(92)70103-m.
3
Efficacy and safety of calcipotriol (MC 903) ointment in psoriasis vulgaris. A randomized, double-blind, right/left comparative, vehicle-controlled study.卡泊三醇（MC 903）软膏治疗寻常型银屑病的疗效与安全性。一项随机、双盲、左右对照、赋形剂对照研究。
J Am Acad Dermatol. 1992 Dec;27(6 Pt 1):983-8. doi: 10.1016/0190-9622(92)70299-u.
4
A multicentre, parallel-group comparison of calcipotriol ointment and short-contact dithranol therapy in chronic plaque psoriasis.
Br J Dermatol. 1992 Sep;127(3):266-71. doi: 10.1111/j.1365-2133.1992.tb00126.x.
Zotero 插件